BioNTech (22UA GY/BNTX) Q1 2026 (EUR): adj. EPS -1.95 (prev. -1.73), Revenue 118mln (exp. 179mln)
- To cut 1.86k jobs.
Context
BioNTech's Q1 2026 results show a miss on both adjusted EPS and revenue compared to expectations, indicating potential struggles in their current operations. The announcement of significant job cuts suggests a strategic shift that could indicate deeper issues within the company, impacting investor sentiment and potentially influencing the biotech sector as a whole.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#EU SESSION#US EQUITIES#EUROPEAN EQUITIES#GLOBAL EQUITIES